Key Points
- CEO Marino Garcia sold 166,000 Dianthus Therapeutics shares at an average price of $108.11, generating approximately $17.95 million. The sale reduced his direct holdings by 71.77% to 65,292 shares.
- DNTH recently reported a quarterly loss of $0.90 per share, missing estimates by $0.05, while revenue of $0.76 million exceeded consensus expectations. Analysts project a full-year loss of $3.94 per share.
- Institutional ownership stands at 47.53%, with BlackRock initiating a position worth about $402 million. Despite one sell rating, the stock has a “Moderate Buy” consensus and an average analyst price target of $124.27.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CEO Marino Garcia sold 166,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer directly owned 65,292 shares of the company's stock, valued at $7,058,718.12. The trade was a 71.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Dianthus Therapeutics Trading Down 0.9%
DNTH stock opened at $108.92 on Friday. The firm's 50-day moving average price is $94.72 and its two-hundred day moving average price is $80.65. Dianthus Therapeutics, Inc. has a 12-month low of $18.08 and a 12-month high of $114.55. The stock has a market capitalization of $5.95 billion, a price-to-earnings ratio of -26.25 and a beta of 1.22.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.94 EPS for the current year.
Institutional Investors Weigh In On Dianthus Therapeutics
Several hedge funds have recently bought and sold shares of DNTH. BlackRock Inc. purchased a new stake in Dianthus Therapeutics in the second quarter worth about $401,990,000. Deutsche Bank AG bought a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $6,800,000. TimesSquare Capital Management LLC purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $16,216,000. Persistent Asset Partners Ltd purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $543,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $93,000. Institutional investors own 47.53% of the company's stock.
Wall Street Analysts Forecast Growth
DNTH has been the subject of several research analyst reports. Guggenheim reiterated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Truist Financial boosted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. HC Wainwright raised their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $124.27.
Get Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
